关于埃诺沙巴林在非手术患者中的药理作用的最新情况
Egidio Imbalzano1, Luana Orlando1, Giuseppe Dattilo1
1Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.
Medicina (Kaunas, Lithuania)
|January 23, 2024
概括
埃诺沙巴林是一种低分子量肝素,在非手术患者中有效预防静脉血栓栓塞 (VTE). 本综述强调了其在需要抗血栓预防的各种疾病中的临床应用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血栓形成研究研究
- 临床医学 临床医学
背景情况:
- 低分子量肝素 (LMWHs) 是从未分离的肝素中衍生出来的.
- 埃诺沙巴林是一种广泛使用的LMWH.
- 在治疗血栓栓塞性疾病方面,LMWHs至关重要.
研究的目的:
- 审查使用enoxaparin的临床经验.
- 专注于预防非手术患者的静脉血栓塞栓症 (VTE).
- 巩固目前关于埃诺沙巴林抗血栓应用的知识.
主要方法:
- 对埃诺沙帕林临床研究的文献综述.
- 对埃诺沙巴林的疗效和安全性分析.
- 综合来自各种临床环境的数据.
主要成果:
- 埃诺沙巴林是广泛研究的VTE预防和治疗.
- 它的使用已在急性冠状动脉综合征中得到证实.
- 埃诺沙巴林也应用于血液透析和预防复发性堕胎.
结论:
- 埃诺沙巴林在非手术患者的VTE预防中显示出显著的临床效用.
- 它的抗血栓性质扩展到各种临床场景.
- 进一步的研究继续定义埃诺沙巴林在抗凝治疗中的作用.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
Antihypertensive Drugs: Vasodilators
526
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
526
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166


